In theory, this mechanism alleviates the PD-1/PD-L1–mediated inhibition imposed by tumor cells or immunosuppressive populations, indirectly enhancing the cytotoxic and cytokine-secreting capabilities of T cells and, consequently, partially restoring anti-tumor immune function. This evidence concerns the gene PDCD1 and neoplasm.